MA48728B1 - Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate - Google Patents

Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate

Info

Publication number
MA48728B1
MA48728B1 MA48728A MA48728A MA48728B1 MA 48728 B1 MA48728 B1 MA 48728B1 MA 48728 A MA48728 A MA 48728A MA 48728 A MA48728 A MA 48728A MA 48728 B1 MA48728 B1 MA 48728B1
Authority
MA
Morocco
Prior art keywords
niraparib
prednisone
prostate cancer
abiraterone acetate
treatment
Prior art date
Application number
MA48728A
Other languages
English (en)
French (fr)
Other versions
MA48728A (fr
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48728(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA48728A publication Critical patent/MA48728A/fr
Publication of MA48728B1 publication Critical patent/MA48728B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MA48728A 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate MA48728B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (2)

Publication Number Publication Date
MA48728A MA48728A (fr) 2020-04-08
MA48728B1 true MA48728B1 (fr) 2022-10-31

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48728A MA48728B1 (fr) 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate

Country Status (33)

Country Link
US (4) US20180296574A1 (https=)
EP (3) EP4176878A1 (https=)
JP (3) JP7141408B2 (https=)
KR (2) KR20260048358A (https=)
CN (2) CN110753545A (https=)
AU (2) AU2018251594A1 (https=)
CA (1) CA3059562A1 (https=)
CL (1) CL2019002871A1 (https=)
CO (1) CO2019011591A2 (https=)
CR (1) CR20190467A (https=)
DK (1) DK3609497T3 (https=)
DO (1) DOP2019000264A (https=)
EA (1) EA201992430A1 (https=)
ES (1) ES2931052T3 (https=)
HR (1) HRP20221327T1 (https=)
HU (1) HUE060460T2 (https=)
IL (2) IL269879B2 (https=)
JO (2) JOP20190244B1 (https=)
LT (1) LT3609497T (https=)
MA (1) MA48728B1 (https=)
MD (1) MD3609497T2 (https=)
MX (2) MX2019012296A (https=)
MY (1) MY209010A (https=)
NI (1) NI201900105A (https=)
PE (1) PE20200444A1 (https=)
PH (1) PH12019502317A1 (https=)
PL (1) PL3609497T3 (https=)
PT (1) PT3609497T (https=)
RS (1) RS63832B1 (https=)
SG (1) SG11201909552VA (https=)
SM (1) SMT202200467T1 (https=)
UA (1) UA129514C2 (https=)
WO (1) WO2018191141A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
TWI905184B (zh) * 2020-05-08 2025-11-21 比利時商健生藥品公司 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
WO2022200982A1 (en) * 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
EP3609497B1 (en) 2022-10-12
RS63832B1 (sr) 2023-01-31
KR20190134718A (ko) 2019-12-04
JP7407880B2 (ja) 2024-01-04
PL3609497T3 (pl) 2023-01-23
JP2022141881A (ja) 2022-09-29
MX2019012296A (es) 2019-11-28
PT3609497T (pt) 2023-01-23
MX2023009569A (es) 2023-08-22
JP2024023344A (ja) 2024-02-21
NI201900105A (es) 2020-03-11
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
UA129514C2 (uk) 2025-05-21
IL320452A (en) 2025-06-01
US20240398837A1 (en) 2024-12-05
PE20200444A1 (es) 2020-02-28
MD3609497T2 (ro) 2023-03-31
MA48728A (fr) 2020-04-08
MY209010A (en) 2025-06-16
CL2019002871A1 (es) 2019-12-27
CO2019011591A2 (es) 2020-02-28
EA201992430A1 (ru) 2020-02-28
JP2020516646A (ja) 2020-06-11
PH12019502317A1 (en) 2020-07-06
ES2931052T3 (es) 2022-12-23
WO2018191141A1 (en) 2018-10-18
CN110753545A (zh) 2020-02-04
SG11201909552VA (en) 2019-11-28
HUE060460T2 (hu) 2023-03-28
JOP20230159A1 (ar) 2023-07-13
DK3609497T3 (da) 2022-10-31
AU2024202346A1 (en) 2024-05-02
AU2024202346B2 (en) 2026-01-22
US20220175801A1 (en) 2022-06-09
AU2018251594A1 (en) 2019-10-24
JP7141408B2 (ja) 2022-09-22
IL269879A (https=) 2019-11-28
US20180296574A1 (en) 2018-10-18
CA3059562A1 (en) 2018-10-18
BR112019021466A2 (pt) 2020-05-12
CN119235874A (zh) 2025-01-03
CR20190467A (es) 2020-03-09
SMT202200467T1 (it) 2023-01-13
LT3609497T (lt) 2022-12-12
IL269879B1 (en) 2025-06-01
EP3609497A1 (en) 2020-02-19
EP4176878A1 (en) 2023-05-10
JOP20190244B1 (ar) 2024-04-18
DOP2019000264A (es) 2020-07-15
HRP20221327T1 (hr) 2023-03-17
IL269879B2 (en) 2025-10-01
KR20260048358A (ko) 2026-04-09
EP4176879A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
MA48728B1 (fr) Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA202091144A1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
MA38493A1 (fr) Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
EP3908601A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
SA523440622B1 (ar) أجسام مضادة
EP3723733A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH EXOSOME-ASSOCIATED GENE EDITING
EP4149547A4 (en) Compositions and methods for treating cancer
EP3347010A4 (en) SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
EP3817774A4 (en) COMPOSITIONS AND METHODS FOR LOCAL ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MA50341A (fr) Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique
JOP20220292A1 (ar) صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب
EP3987032A4 (en) Methods and compositions for the treatment of cancer
EP3865141A4 (en) ANTI-CANCER AGENT, PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND KIT
MY204443A (en) Pyridopyrimidinone derivatives for use as axl inhibitors
EP3890715A4 (en) ANTI-ADENOMATOUS POLYPOSIS COLI (APC) THERAPEUTICS FOR THE TREATMENT OF CANCER
MA55888B1 (fr) Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
WO2024220955A3 (en) Combining induction of ferroptosis with targeted agents for cancer therapy
MA55892B1 (fr) Phénylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation
EP3844262A4 (en) PEPTIDE THERAPEUTICS FOR THE TREATMENT OF CANCER AND USES THEREOF
EP4153137A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR MANUFACTURE FOR THE TREATMENT OF CANCER